Authors' Reports

Gabriele Fragasso
describes for SIIC the most significant aspects of his article
describe para SIIC los aspectos relevantes de su artículo

Real world indications to ivabradine treatment in chronic systolic heart failure

In a carefully managed population of patients with moderate, stable heart failure with reduced ejection fraction (HFrEF), where optimal guidelines directed medical therapy (GDMT) is properly attained, the indication to ivabradine treatment is around 17%. This percentage represents that group of patients who, either do not tolerate beta-blockers or who have an uncontrolled heart rate despite the maximum tolerated dose of beta-blockers.

The article was published by
El artículo fue publicado por
Journal of Cardiovascular Medicine
Volume / Volumen: 19
Number / Número: 7
First and last pages / Páginas inicial-final: 351-356
Year / Año: 2018
Month / Mes: july

Principal institution where the research took place
Institución principal de la investigación

Authors' Report

Crónica del Autor

Indicaciones en la Práctica Diaria para el Tratamiento con Ivabradina en la Insuficiencia Cardíaca Sistólica Crónica

En una población meticulosamente controlada de enfermos con insuficiencia cardíaca estable moderada, fracción de eyección reducida, y cumplimiento de las recomendaciones de tratamiento médico óptimo, la indicación de ivabradina tiene lugar en alrededor del 17% de los casos. Este porcentaje es representativo del grupo de pacientes que no toleran el tratamiento con betabloqueantes o que tienen control inadecuado de la frecuencia cardíaca, a pesar de utilizar la dosis máxima tolerada de betabloqueantes.
Crónica del Autor

Imprimir nota

Bibliographic references
Referencias bibliográficas

1. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875-85, 2010.
2. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo- controlled trial. Lancet 6;372(9641):807-16, 2008.
3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 18:891-975, 2016.
4. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 22:659-69, 2016.
5. Tondi L, Fragasso G, Spoladore R, et al. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. J Cardiovasc Med (Hagerstown) 19(7):351-356, 2018.
6. Spoladore R, Fragasso G, Perseghin G, et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundam Clin Pharmacol 27:455-64, 2013.
7. Fragasso G, Salerno A, Margonato A. Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure. Am J Cardiol 102:506-7, 2008.
8. Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:1173-84, 2013.

Other articles written by the author Gabriele Fragasso
Otros artículos de Gabriele Fragasso

SIIC System of Assisted Editing (SSEA)
/ Sistema SIIC de Edición Asistida (SSEA)

Gabriele Fragasso was invited by SIIC on
Gabriele Fragasso fue invitado por SIIC el
2018, september 7
  The authors' report was accepted on
La crónica del autor fue aprobada el
2022, august 13
The authors' report was accepted on
La crónica del autor fue aprobada el
2022, august 13
Published in siicsalud
Publicado en siicsalud
2022, november 11

The article is strictly related to the following sections of siicsalud
El artículo se relaciona estrictamente con las siguientes secciones de siicsalud

/ Cardiología
Pharmaceutical Medicine
/ Medicina Farmacéutica

and secondarily related to the following sections

y secundariamente con las siguientes secciones


Internal Medicine
Medicina Interna

Information about the full text
Acerca del trabajo completo

Real-Life Indications to Ivabradine Treatment for Heart Rate Optimization in Patients with Chronic Systolic Heart Failure

Access to the original source
Journal of Cardiovascular Medicine

Article URL:
/ URL del artículo:;jsessionid=JLMYBRnyLTF0pSBKb5yQQpyn1mRXcDl472yDLJQJTqq6pcKjKRxk!-348297060!181195629!8091!-1

URL of Abstract:
/ URL del abstract:

URL of Abstract page in Medline:
/ URL del abstract en Medline:

URL of Abstract page in Scielo:
/ URL del abstract en Scielo:

URL of Abstract page in Scopus:
/ URL del abstract en Scopus:

URL of Abstract page in Embase:
/ URL del abstract en Embase:

Other data bases:
/ Otras bases de datos:

siic DB:
/ siic DB: